Journal
GENES & DEVELOPMENT
Volume 24, Issue 7, Pages 708-719Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.568410
Keywords
Steroid receptor; signaling; coactivator; protein kinase A; breast cancer; endocrine resistance
Categories
Funding
- Canton de Geneve
- Swiss National Science Foundation
- Fondation Medic
Ask authors/readers for more resources
The estrogen receptor alpha (ER alpha) is activated as a transcription factor by both estrogen and a large variety of other extracellular signals. The mechanisms of this ligand-independent activation, notably by cAMP signaling, are still largely unknown. We now close the gap in the signaling pathway between cAMP and ER alpha. Whereas the direct phosphorylation of ER alpha by the cAMP-activated protein kinase A (PKA) is dispensable, the phosphorylation of the coactivator-associated arginine methyltransferase 1 (CARM1) by PKA at a single serine is necessary and sufficient for direct binding to the unliganded hormone-binding domain (HBD) of ER alpha, and the interaction is necessary for cAMP activation of ER alpha. Sustained PKA activity promoting a constitutive interaction may contribute to tamoxifen resistance of breast tumors. Binding and activation involve a novel regulatory groove of the ER alpha HBD. As a result, depending on the activating signal, ERa recruits different coactivator complexes to regulate alternate sets of target genes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available